A review of antidepressant therapy in primary care: Current practices and future directions

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 15, Issue 2, 2013, Pages

  Kennedy, Sidney H ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; DEXMETHYLPHENIDATE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; LIOTHYRONINE; LITHIUM CARBONATE; LITHIUM SALT; LU AA 21004; METHYLPHENIDATE; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRANYLCYPROMINE; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE; VORTIOXETINE;

ADD ON THERAPY; ANTIDEPRESSANT ACTIVITY; APATHY; ARTICLE; BINDING AFFINITY; COGNITIVE THERAPY; COMORBIDITY; DISEASE SEVERITY; DRUG APPROVAL; DRUG BINDING; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY UNIT; EMBASE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; NEUROENDOCRINE DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHOTHERAPY; RECURRENT DISEASE; REHABILITATION CARE; RELAPSE; REMISSION; RISK FACTOR; SELF HELP; SEXUAL DYSFUNCTION; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; SYMPTOM; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84877680920     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.12r01420     Document Type: Article

References (100)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747-1757. PubMed doi:10.1016/S0140-6736(06)68770-9
2. Collins PY, Patel V, Joestl SS, et al; Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health. Grand challenges in global mental health. Nature. 2011;475(7354):27-30.PubMed doi:10.1038/475027a
3. Langlieb AM, Guico-Pabia CJ. Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2): e1-e14. 10.4088/PCC.09r00826blu PubMed
4. Eaton WW, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5):513-520.PubMed doi:10.1001/archpsyc.65.5.513
5. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000;22(3):153-162. PubMed doi:10.1016/S0163-8343(00)00072-4
6. Simon GE, Khandker RK, Ichikawa L, et al. Recovery from depression predicts lower health services costs. JClin Psychiatry. 2006;67(8):1226-1231.PubMed doi:10.4088/JCP.v67n0808
7. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-627.PubMed doi:10.1001/archpsyc.62.6.617
8. Shim RS, Baltrus P, Ye J, et al. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008. JAm Board Fam Med. 2011;24(1):33-38.PubMed doi:10.3122/jabfm.2011.01.100121
9. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737-1744.PubMed doi:10.1001/jama.282.18.1737
10. Béland SG, Tournier M, Galbaud du Fort G, et al. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach. Value Health. 2011;14(4):492-498.PubMed doi:10.1016/j.jval.2010.11.015
11. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449-459.doi:10.1007/s11920-007-0061-3 PubMed
12. Mattisson C, Bogren M, Horstmann V, et al. The long-term course of depressive disorders in the Lundby study. Psychol Med. 2007;37(6):883-891.PubMed doi:10.1017/S0033291707000074
13. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000-1006.PubMed
14. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171-1180.PubMed doi:10.1017/S0033291700033146
15. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-1504.PubMed doi:10.1176/appi.ajp.157.9.1501
16. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. JClin Psychiatry. 1999;60(suppl 22):7-11.PubMed
17. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.PubMed doi:10.1016/S0140-6736(09)60046-5
18. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.PubMed doi:10.1176/appi.ajp.163.1.28
19. Williamson PS, Yates WR. The initial presentation of depression in family practice and psychiatric outpatients. Gen Hosp Psychiatry.1989;11(3):188-193; discussion 216-121.
20. Schwenk TL, Coyne JC, Fechner-Bates S. Differences between detected and undetected patients in primary care and depressed psychiatric patients. Gen Hosp Psychiatry. 1996;18(6):407-415.PubMed doi:10.1016/S0163-8343(96)00062-X
21. Cooper-Patrick L, Crum RM, Ford DE. Characteristics of patients with major depression who received care in general medical and specialty mental health settings. Med Care. 1994;32(1):15-24.PubMed doi:10.1097/00005650-199401000-00002
22. Gaynes BN, Rush AJ, Trivedi MH, et al. Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann Fam Med. 2007;5(2):126-134. PubMed doi:10.1370/afm.641
23. Stegenga BT, Kamphuis MH, King M, et al. The natural course and outcome of major depressive disorder in primary care: the PREDICT-NL study. Soc Psychiatry Psychiatr Epidemiol. 2012;47(1):87-95.PubMed doi:10.1007/s00127-010-0317-9
24. Rucci P, Frank E, Calugi S, et al. Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination. Depress Anxiety. 2011;28(11):955-962.PubMed doi:10.1002/da.20894
25. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627-647.PubMed
26. Hamilton M. A rating scale for depression. JNeurol Neurosurg Psychiatry. 1960;23(1):56-62. PubMed doi:10.1136/jnnp.23.1.56
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.PubMed doi:10.1192/bjp.134.4.382
28. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653-661.PubMed doi:10.1016/S0140-6736(03)12599-8
29. Glue P, Donovan MR, Kolluri S, et al. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N Z J Psychiatry. 2010;44(8):697-705.PubMed doi:10.3109/00048671003705441
30. Patten SB, Kennedy SH, Lam RW, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults, 1: classification, burden and principles of management. JAffect Disord. 2009;117(suppl 1):S5-S14.PubMed doi:10.1016/j.jad.2009.06.044
31. Kupfer DJ. Long-term treatment of depression. JClin Psychiatry. 1991;52(suppl):28-34. PubMed
32. National Institute for Health and Clinical Excellence. Depression: The Treatment and Management of Depression in Adults. Leicester, UK: British Psychological Society; 2010.
33. Gelenberg AJ, Freeman MP, Markowitz JC, et al; American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
34. Lam RW, Kennedy SH, Grigoriadis S, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults, 3: pharmacotherapy. JAffect Disord. 2009;117(suppl 1):S26-S43.PubMed doi:10.1016/j.jad.2009.06.041
35. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. JPsychopharmacol. 2008;22(4):343-396.PubMed doi:10.1177/0269881107088441
36. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155(11):772-785.PubMed
37. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445.PubMed doi:10.1176/appi.ps.60.11.1439
38. Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689-701.PubMed doi:10.1176/appi.ajp.2011.10111645
39. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.PubMed doi:10.1176/appi.ajp.163.11.1905
40. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739-752.PubMed doi:10.1176/appi.ajp.164.5.739
41. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288.PubMed doi:10.1176/appi.ajp.2009.09020186
42. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457-465.PubMed doi:10.1016/j.euroneuro.2009.01.015
43. Iovieno N, van Nieuwenhuizen A, Clain A, et al. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety. 2011;28(2):137-144.PubMed doi:10.1002/da.20768
44. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):41-50.PubMed doi:10.1017/S0033291709006011
45. McKinnon MC, Yucel K, Nazarov A, et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. JPsychiatry Neurosci. 2009;34(1):41-54.PubMed
46. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. JClin Psychiatry. 2006;67(11):1754-1759.PubMed doi:10.4088/JCP.v67n1113
47. Biringer E, Rongve A, Lund A. A review of modern antidepressants' effects on neurocognitive function. Curr Psychiatry Rev. 2009;5(3):1-11.
48. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. JAffect Disord. 2011;134(1-3):20-31.PubMed doi:10.1016/j.jad.2010.11.011
49. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms uring depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2010;8:1-10. PubMed
50. Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. JAffect Disord. 2011;132(suppl 1):S9-S13.PubMed doi:10.1016/j.jad.2011.03.046
51. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribner and Sons; 1983.
52. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2007;23(7):1605-1614.PubMed doi:10.1185/030079907X210732
53. Sapin C, Fantino B, Nowicki ML, et al. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004;2(1):20.PubMed doi:10.1186/1477-7525-2-20
54. Zimmerman M, Ruggero CJ, Chelminski I, et al. Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life. JClin Psychiatry. 2006;67(10):1536-1541.doi:10.4088/JCP.v67n1007 PubMed
55. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. JClin Psychiatry. 2007;68(8):1246-1256.PubMed doi:10.4088/JCP.v68n0812
56. Perahia DG, Maina G, Thase ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. JClin Psychiatry. 2009;70(5):706-716. PubMed doi:10.4088/JCP.08m04756
57. Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. JClin Psychiatry. 2006;67(11):1767-1775.PubMed doi:10.4088/JCP.v67n1115
58. Thase ME, Gelenberg A, Kornstein SG, et al. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. JPsychiatr Res. 2011;45(3):412-420.PubMed doi:10.1016/j.jpsychires.2010.07.009
59. Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology. 2010;62(1):36-42.PubMed doi:10.1159/000314308
60. Nierenberg, AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry, 2006;163(9):1519-1530; quiz 1665.
61. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. JClin Psychiatry. 2008;69(1):87-94.PubMed doi:10.4088/JCP.v69n0112
62. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57-90.PubMed
63. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. JClin Psychiatry. 2009;70(suppl 6):16-25.PubMed doi:10.4088/JCP.8133su1c.03
64. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. JClin Psychiatry. 2007;68(6):843-853.PubMed doi:10.4088/JCP.v68n0604
65. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23(6):364-372.PubMed doi:10.1002/da.20130
66. Liu X, Chen Y, Faries DE. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinicoecon Outcomes Res. 2011;3:63-72.PubMed
67. Zimmerman M, Galione JN, Attiullah N, et al. Underrecognition of clinically significant side effects in depressed outpatients. JClin Psychiatry. 2010;71(4):484-490.PubMed doi:10.4088/JCP.08m04978blu
68. Ginsberg LD. Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS Spectr. 2009;14(suppl 12):8-14.PubMed
69. Patten SB, Williams JV, Lavorato DH, et al. Weight gain in relation to major depression and antidepressant medication use. JAffect Disord. 2011;134(1-3):288-293.PubMed doi:10.1016/j.jad.2011.06.027
70. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. JClin Psychiatry. 2010;71(10):1259-1272.PubMed doi:10.4088/JCP.09r05346blu
71. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. JClin Psychopharmacol. 2009;29(2):157-164.PubMed doi:10.1097/JCP.0b013e31819c76e9
72. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141-150.PubMed doi:10.2147/DHPS.S7634
73. Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care. 2002;38(3):111-116.PubMed doi:10.1111/j.1744-6163.2002.tb00665.x
74. Meyer JH, Cho R, Kennedy S, et al. The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology (Berl). 1999;144(3):279-281.PubMed doi:10.1007/s002130051004
75. Montejo AL, Llorca G, Izquierdo JA, et al; Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. JClin Psychiatry. 2001;62(suppl 3):10-21.PubMed
76. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. JAffect Disord. 2005;88(3):241-254.PubMed doi:10.1016/j.jad.2005.07.006
77. Clayton AH, Dennerstein L, Pyke R, et al. Flibanserin: a potential treatment for hypoactive sexual desire disorder in premenopausal women. Womens Health (Lond Engl). 2010;6(5):639-653.PubMed doi:10.2217/whe.10.54
78. Undurraga J, Baldessarini RJ, Valentí M, et al. Bipolar depression: clinical correlates of receiving antidepressants. JAffect Disord. 2012;139(1):89-93.PubMed doi:10.1016/j.jad.2012.01.027
79. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry. 2011;68(12):1227-1237.PubMed doi:10.1001/archgenpsychiatry.2011.132
80. McCabe C, Mishor Z, Cowen PJ, et al. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2010;67(5):439-445.PubMed doi:10.1016/j.biopsych.2009.11.001
81. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, et al. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30(11):3719-3735.PubMed doi:10.1002/hbm.20801
82. Papakostas GI. Surrogate markers of treatment outcome in major depressive disorder. Int J Neuropsychopharmacol. 2012;15(6):841-854.PubMed doi:10.1017/S1461145711001246
83. Kennedy SH, Downar J, Evans KR, et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976-5989.PubMed
84. Rizvi SJ, Kennedy SH. Emerging drugs for major depressive disorder: an update. Expert Opin Emerg Drugs. 2012;17(3):285-294.PubMed doi:10.1517/14728214.2012.681301
85. Crisafulli C, Fabbri C, Porcelli S, et al. Pharmacogenetics of antidepressants. Front Pharmacol. 2011;2:6.PubMed doi:10.3389/fphar.2011.00006
86. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607-611.PubMed doi:10.1002/da.20589
87. Maas DW, Westendorp RG, Willems JM, et al. TNF-α antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial. JClin Psychopharmacol. 2010;30(3):343-345.PubMed doi:10.1097/JCP.0b013e3181dcf0de
88. Müller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs. 2010;11(1):31-42.PubMed
89. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127.PubMed doi:10.1016/j.biopsych.2006.02.013
90. Rantamäki T, Hendolin P, Kankaanpää A, et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology. 2007;32(10):2152-2162.PubMed doi:10.1038/sj.npp.1301345
91. Watanabe K, Hashimoto E, Ukai W, et al. Effect of antidepressants on brain-derived neurotrophic factor (BDNF) release from platelets in the rats. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1450-1454.PubMed doi:10.1016/j.pnpbp.2010.07.036
92. Sanacora G, Kendell SF, Fenton L, et al. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry. 2004;161(11):2132.PubMed doi:10.1176/appi.ajp.161.11.2132
93. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. JClin Psychopharmacol. 2008;28(6):631-637.PubMed doi:10.1097/JCP.0b013e31818a6cea
94. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.PubMed doi:10.1001/archpsyc.63.8.856
95. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65(2):181-184.PubMed doi:10.1016/j.biopsych.2008.09.029
96. McEwen BS, Chattarji S, Diamond DM, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry. 2010;15(3):237-249.doi:10.1038/mp.2009.80 PubMed
97. Moore NA, Bang-Andersen B, Brennum LT, et al. P.2.b.015 Lu AA21004: a novel potential treatment for mood disorders. Eur Neuropsychopharmacol. 2008;18(suppl 4):S321. doi:10.1016/S0924-977X(08)70440-1
98. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482-491. PubMed doi:10.1016/j.euroneuro.2011.11.008
99. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. JPsychopharmacol. 2012;26(11):1408-1416. PubMed doi:10.1177/0269881112441866
100. Prins J, Denys DA, Westphal KG, et al. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol. 2010;633(1-3):55-61.PubMed doi:10.1016/j.ejphar.2010.02.009